Nano-hole induction by nanodiamond and nanoplatinum liquid, DPV576, reverses multidrug resistance in human myeloid leukemia (HL60/AR)

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 2567-2573

  Ghoneum, Alia ^a,b   Sharma, Shivani ^a   Gimzewski, James ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DREW UNIVERSITY   (United States)

Author keywords

AFM; Daunorubicin; Flow cytometry; Nanodiamond; Nanoplatinum

Indexed keywords

ANTINEOPLASTIC AGENT; DAUNORUBICIN; DPV 576; NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; ATOMIC FORCE MICROSCOPY; CANCER RESISTANCE; CELL ASSAY; CELL STRAIN HL 60; CELL SURVIVAL; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG MIXTURE; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; MYELOID LEUKEMIA;

AFM; DAUNORUBICIN; FLOW CYTOMETRY; NANODIAMOND; NANOPLATINUM;

CELL LINE, TUMOR; CELL MEMBRANE; CELL SURVIVAL; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID; MICROSCOPY, ATOMIC FORCE; NANODIAMONDS; NANOMEDICINE; PLATINUM;

EID: 84880612325     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S43417     Document Type: Article

References (53)

1. Lu J, Liong M, Sherman S, et al. Mesoporous silica nanoparticles for cancer therapy: energy-dependent cellular uptake and delivery of paclitaxel to cancer cells. Nanobiotechnology. 2007;3(2):89-95.
2. Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjug Chem. 2008;19(12):2321-2331.
3. Yousefpour P, Atyabi F, Vasheghani-Farahani E, Movahedi AA, Dinarvand R. Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab. Int J Nanomedicine. 2011;6:1977-1990.
4. Chen T, Cheng T, Chen C, et al. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J Biol Inorg Chem. 2009;14(2):253-260.
5. Sun B, Ranganathan B, Feng SS. Multifunctional poly (D, L-lactide-coglycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials. 2008;29(4):475-486.
6. Cirstoiu-Hapca A, Bossy-Nobs L, Buchegger F, Gurny R, Delie F. Differential tumor cell targeting of anti-HER2 (Herceptin®) and anti-CD20 (Mabthera®) coupled nanoparticles. Int J Pharm. 2007;331(2): 190-196.
7. Guo D, Wu C, Li J, et al. Synergistic effect of functionalized nickel nanoparticles and Quercetin on inhibition of the SMMC-7721 cells proliferation. Nanoscale Res Lett. 2009;4(12):1395-1402.
8. Steinhauser I, Spänkuch B, Strebhardt K, Langer K. Trastuzumab modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials. 2006;27(28):4975-4983.
9. Steinhauser IM, Langer K, Strebhardt KM, Spänkuch B. Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation. Biomaterials. 2008;29(29):4022-4028.
10. Sharma S, Santiskulvong C, Bentolila LA, Rao J, Dorigo O, Gimzewski JK. Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells. Nanomedicine. 2012;8(5): 757-766.
11. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1999;339(13):900-905.
12. Francis PA, Kris MG, Rigas JR, Grant SC, Miller VA. Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Lung Cancer. 1995;1:S163-S172.
13. Fossella FV, Lee JS, Berille J, Hong WK. Summary of phase II data of docetaxel (Taxotere), an active agent in the first-and second-line treatment of advanced non-small cell lung cancer. Semin Oncol. 1995;22(2):22-29.
14. Strauss GM, Lynch TJ, Elias AD, et al. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer. Semin Oncol. 1995;22(4):70-74.
15. Sanderson BJ, Ferguson LR, Denny WA. Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutat Res. 1996; 355(1-2):59-70.
16. Santin AD, Hermonat PL, Ravaggi A, et al. Effects of concurrent cisplatinum administration during radiotherapy vs radiotherapy alone on the immune function of patients with cancer of the uterine cervix. Int J Radiat Oncol Biol Phys. 2000;48(4):997-1006.
17. Gollapudi S, Kim CH, Tran BN, Sangha S, Gupta S. Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells. Cancer Chemother Pharmacol. 1997;40(2):150-158.
18. Versantvoort CH, Schuurhuis GJ, Pinedo HM, et al. Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer. 1993;68(5):939-946.
19. Chuman Y, Chen ZS, Seto K, et al. Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK-104P. Cancer Lett. 1998;129(1):69-76.
20. Phillips PC. Antineoplastic drug resistance in brain tumors. Neurol Clin. 1991;9(2):383-404.
21. Ghoneum M, Ghoneum A, Gimzewski J. Nanodiamond and nanoplatinum liquid, DPV576, activates human monocyte-derived dendritic cells in vitro. Anticancer Res. 2010;30(10):4075-4079.
22. Ghoneum M, Ghoneum A, Tolentino L, Gimzewski J. Modulation of aged murine T lymphocytes in vivo by DPV576-C, a nanodiamond-and nanoplatinum-coated material. In Vivo. 2010;24(2):141-146.
23. Sharma S, Rasool HI, Palanisamy V, et al. Structural-mechanical characterization of nanoparticle exosomes in human saliva, using correlative AFM, FESEM, and force spectroscopy. ACS Nano. 2010;4(4):1921-1926.
24. Petrou I, Heu R, Stranick M, et al. A breakthrough therapy for dentin hypersensitivity: how dental products containing 8% arginine and calcium carbonate work to deliver effective relief of sensitive teeth. J Clin Dent. 2009;20(1):23-31.
25. Kumagai K, Itoh K, Suzuki R, Hinuma S, Saitoh F. Studies of murine large granular lymphocytes. I. Identification as effector cells in NK and K cytotoxicities. J Immunol. 1982;129(1):388-394.
26. Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science. 2004;303:1818-1822.
27. Choleris E, Little SR, Mong JA, Puram SV, Langer R, Pfaff DW. Microparticle-based delivery of oxytocin receptor antisense DNA in the medial amygdala blocks social recognition in female mice. Proc Natl Acad Sci U S A. 2007;104:4670-4675.
28. Misra R, Sahoo SK. Coformulation of doxorubicin and curcumin in poly(D, L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm. 2011;8(3):852-866.
29. Chen BA, Lai BB, Cheng J, et al. Daunorubicin-loaded magnetic nanoparticles of Fe3O4 overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo. Int J Nanomedicine. 2009;4: 201-208.
30. Sano N, Shibata M, Izumi K, Otsuka H. Histopathological and immunohistochemical studies on nickel sulfide-induced tumors in F344 rats. Jpn J Cancer Res. 1988;79:212-221.
31. Phillips JI, Green FY, Davies JC, Murray J. Pulmonary and systemic toxicity following exposure to nickel nanoparticle. Am J Ind Med. 2010;53:763-767.
32. Lison D, De Boeck M, Verougstraete V, Kirsch-Volders M. Update on the genotoxicity and carcinogenicity of cobalt compounds. Occup Environ Med. 2001;58:619-662.
33. Hansen T, Clermont G, Alves A, et al. Biological tolerance of different materials in bulk and nanoparticulate form in a rat model: sarcoma development by nanoparticles. J R Soc Interface. 2006;3(11): 767-775.
34. Schrand AM, Huang H, Carlson C, et al. Are diamond nanoparticles cytotoxic? J Phys Chem B. 2007;111(1):2-7.
35. Yuan Y, Wang X, Jia G, et al. Pulmonary toxicity and translocation of nanodiamond in mice. Diam Relat Mater. 2010;19:291-299.
36. Xing Y, Dai L. Nanodiamonds for nanomedicine. Nanomedicine. 2009;4(2):207-218.
37. Mochalin VN, Shenderova O, Ho D, Gogotsi Y. The properties and applications of nanodiamonds. Nat Nanotechnol. 2011;7(1):11-23.
38. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219-234.
39. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615-627.
40. Verma A, Uzun O, Hu Y, et al. Surface structure-regulated cell membrane penetration by monolayer protected nanoparticles. Nat Mater. 2008;7(7):588-595.
41. Leroueil PR, Hong SY, Mecke A, Baker JR, Orr BG, Holl MM. Nanoparticle interaction with biological membranes: Does nanotechnology present a janus face? Accounts Chem Res. 2007;40:335-342.
42. Ruenraroengsak P, Novak P, Berhanu D, et al. Respiratory epithelial cytotoxicity and membrane damage (holes) caused by amine-modified nanoparticles. Nanotoxicology. 2012;6(1):94-108.
43. Osano E, Kishi J, Takahashi Y. Phagocytosis of titanium particles and necrosis in TNF-alpha resistant mouse sarcoma L929 cells. Toxicol In Vitro. 2003;17(1):41-47.
44. Kiyohara T, Kumakiri M, Kobayashi H, Ohkawara A, Lao LM. Atrophic dermatofibroma. Elastophagocytosis by the tumor cells. J Cutan Pathol. 2000;27(6):312-315.
45. Marin-Padilla M. Erythrophagocytosis by epithelial cells of a breast carcinoma. Cancer. 1977;39(3):1085-1089.
46. Vandenberghe J, Verheyen A, Lauwers S, Geboes K. Spontaneous adenocarcinoma of the ascending colon in Wistar rats: the intracytoplasmic presence of a Campylobacter-like bacterium. J Comp Pathol. 1985;95(1):45-55.
47. Ghoneum M, Grewal I, Brown J, Osborne R, Elembabi H, Gill G. Phagocytosis of candida albicans by lymphatic tumour cells in vitro. Acta Histochem. 2003;105(2):127-133.
48. Ghoneum M, Gollapudi S. Phagocytosis of Candida albicans by metastatic and non metastatic human breast cancer cell lines in vitro. Cancer Detect Prev. 2004;28(1):17-26.
49. Ghoneum M, Hamilton J, Brown J, Gollapudi S. Human squamous cell carcinoma of the tongue and colon undergoes apoptosis upon phagocytosis of Saccharomyces cerevisiae, the baker's yeast, in vitro. Anticancer Res. 2005;25(2A):981-989.
50. Ghoneum M, Salem F, Shum SS, Perry L, Gill G. In situ lymphophagocytosis by nonlymphoreticular neoplasms. Nat Immun Cell Growth Regul. 1987;6(2):77-87.
51. Ghoneum M, Salem F, Allen H, Gill G. Phagocytosis of autologous lymphocytes by cervical preneoplastic and neoplastic cells. Nat Immun Cell Growth Regul. 1988;7(4):239-248.
52. Singhal N, Handa U, Bansal C, Mohan H. Neutrophil phagocytosis by tumor cells-a cytological study. Diagn Cytopathol. 2011;39(8): 553-555.
53. Overholtzer M, Mailleux AA, Mouneimne G, et al. A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion. Cell. 2007;131(5):966-979.